Natural products and their bioactive compounds have been used for centuries to prevent and treat numerous diseases. Kaempferol, a flavonoid found in vegetables, fruits, and spices, is recognized for its various beneficial properties, including its antioxidant and anti-inflammatory potential. This molecule has been identified as a potential means of managing different pathogenesis due to its capability to manage various biological activities. Moreover, this compound has a wide range of health-promoting benefits, such as cardioprotective, neuroprotective, hepatoprotective, and anti-diabetic, and has a role in maintaining eye, skin, and respiratory system health. Furthermore, it can also inhibit tumor growth and modulate various cell-signaling pathways. In vivo and in vitro studies have demonstrated that this compound has been shown to increase efficacy when combined with other natural products or drugs. In addition, kaempferol-based nano-formulations are more effective than kaempferol treatment alone. This review aims to provide detailed information about the sources of this compound, its bioavailability, and its role in various pathogenesis. Although there is promising evidence for its ability to manage diseases, it is crucial to conduct further investigations to know its toxicity, safety aspects, and mechanism of action in health management.

Cancer is the principal cause of death and its incidence is increasing continuously worldwide. Various treatment approaches are in practice to treat cancer, but these treatment strategies may be associated with severe side effects and also produce drug resistance. However, natural compounds have established their role in cancer management with minimal side effects. In this vista, kaempferol, a natural polyphenol, mainly found in vegetables and fruits, has been revealed to have many health-promoting effects. Besides its health-promoting potential, its anti-cancer potential has also been described in in vivo as well as in in vitro studies. The anti-cancer potential of kaempferol has been proven through modulation of cell signaling pathways in addition to the induction of apoptosis and cell cycle arrest in cancer cells. It leads to the activation of tumor suppressor genes, inhibition of angiogenesis, PI3K/AKT pathways, STAT3, transcription factor AP-1, Nrf2 and other cell signaling molecules. Poor bioavailability of this compound is one of the major limitations for its proper and effective disease management actions. Recently, some novel nanoparticle-based formulations have been used to overcome these limitations. The aim of this review is to provide a clear picture regarding the mechanism of action of kaempferol in different cancers through the modulation of cell signaling molecules. Besides this, strategies to improve the efficacy and synergistic effects of this compound have also been described. However, more studies are needed based on clinical trials to fully explore the therapeutic role of this compound, especially in cancer treatment.

Cancer is a major public health concern worldwide and main burden of the healthcare system. Regrettably, most of the currently used cancer treatment approaches such as targeted therapy, chemotherapy, radiotherapy and surgery usually cause adverse complications including hair loss, bone density loss, vomiting, anemia and other complications. However, to overcome these limitations, there is an urgent need to search for the alternative anticancer drugs with better efficacy as well as less adverse complications. Based on the scientific evidences, it is proven that naturally occurring antioxidants present in medicinal plants or their bioactive compounds might constitute a good therapeutic approach in diseases management including cancer. In this regard, myricetin, a polyhydroxy flavonol found in a several types of plants and its role in diseases management as anti-oxidant, anti-inflammatory and hepato-protective has been documented. Moreover, its role in cancer prevention has been noticed through modulation of angiogenesis, inflammation, cell cycle arrest and induction of apoptosis. Furthermore, myricetin plays a significant role in cancer prevention through the inhibition of inflammatory markers such as inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (Cox-2). Moreover, myricetin increases the chemotherapeutic potential of other anticancer drugs through modulation of cell signaling molecules activity. This review elaborates the information of myricetin role in cancer management through modulating of various cell-signaling molecules based on in vivo and in vitro studies. In addition, synergistic effect with currently used anticancer drugs and approaches to improve bioavailability are described. The evidences collected in this review will help different researchers to comprehend the information about its safety aspects, effective dose for different cancers and implication in clinical trials. Moreover, different challenges need to be focused on engineering different nanoformulations of myricetin to overcome the poor bioavailability, loading capacity, targeted delivery and premature release of this compound. Furthermore, some more derivatives of myricetin need to be synthesized to check their anticancer potential.

Cancer is a major public health concern worldwide in terms of mortality. The exact reason behind the development of cancer is not understood clearly, but it is evidenced that alcohol consumption, radiation, and exposure to chemicals are main players in this pathogenesis. The current mode of treatments such as surgery, chemotherapy, and radiotherapy are effective, but, still, cancer is a major problem leading to death and other side effects. However, safer and effective treatment modules are needed to overcome the adverse effects of current treatment modules. In this regard, natural compounds have been recognized to ameliorate diseases by exerting anti-inflammatory, anti-oxidative, and anti-tumor potential through several mechanisms. Mangiferin, a xanthone C-glucoside, is found in several plant species including Mangifera indica (mango), and its role in disease prevention has been confirmed through its antioxidant and anti-inflammatory properties. Furthermore, its anti-cancer-potential mechanism has been designated through modulation of cell signaling pathways such as inflammation, angiogenesis, PI3K/AKT, apoptosis, and cell cycle. This article extensively reviews the anticancer potential of mangiferin in different cancers through the modulation of cell signaling pathways. Moreover, the synergistic effects of this compound with some commonly used anti-cancer drugs against different cancer cells are discussed. More clinical trials should be performed to reconnoiter the anti-cancer potential of this compound in human cancer treatment. Further, understanding of mechanisms of action and the safety level of this compound can help to manage diseases, including cancer.

Background: Polycyclic aromatic hydrocarbons such as Benzo(a)Pyrene, which are produced by smoking or present in air pollution, greatly contribute to lung diseases. B(a)P has been found to induce inflammation and eventually lung cancer. Fisetin, a polyphenol, abundant in many fruits and vegetables, has an appealing therapeutic potential in many disorders, including inflammation and cancer. Objectives: This study aimed to investigate the importance of fisetin in the regulation of chronic lung inflammation and oxidative stress resulting from exposure to Benzo(a)Pyrene. Methods: The effect of fisetin on rats at a concentration of 50 mg/kg was evaluated by ELISA to measure oxidative stress and inflammatory markers. The tissue architecture was also investigated using hematoxylin and eosin (H&E) staining. The expression pattern of IL-6 in lung tissues was assayed using immunohistochemistry. Fibrosis was evaluated in lung tissues using Masson Trischrome and Sirius red stains. Cell apoptosis in lung tissues was studied using a TUNEL assay. Results: After exposure to Benzo(a)Pyrene for eight weeks, the data indicated that fisetin led to a significant reduction in oxidative stress, evidenced by the reduction of SOD, MDA, NO, GPH, and GPx. Moreover, IL-6, TNF-α, and CRP levels were also decreased, indicating a reduction in inflammation. Apoptosis was reduced upon fisetin treatment. Furthermore, a significant decrease in fibrosis was also observed. Conclusions: This study reveals the importance of fisetin as a natural product in the management of chronic lung injury by protecting lung tissues from inflammation, and its use suggests better prognosis in diseases caused by exposure to B(a)P.

Background: Ovarian carcinoma (OC) is one of the foremost factors in female carcinoma-related fatalities worldwide. Matrix metalloproteinases (MMPs) are key mediators of tissue remodeling and are linked to tumor aggressiveness, yet there is still a lack of information on the link between genetic changes in MMPs-1,3 and the onset and progression of OC in Egyptian women. This study examines the effects of immunoreactive biomolecule variations of MMPs-1,3, as well as the MMP-1 (1607 1G/2G) and MMP-3 (-1171 5A/6A) genetic variants, on OC risk and progression in Egyptian women. Methods: Tissue specimens embedded in paraffin from 100 OC patients and 60 controls were stained using immunohistochemistry to examine expression of MMPs-1,3. MMP levels were quantified using ELISA, and single-nucleotide polymorphisms (SNPs) of MMPs-1,3 were genotyped using polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP). Results: Increased levels of MMPs-1,3 in OC patients relative to controls, with more of an increase in the late stages (III and IV) than in the early OC stages (I and II). Additionally, the MMP-1 2G/2G and MMP-3 6A/6A genotypes were more prevalent in OC patients than in controls. Ovarian MMPs-1,3 were comparatively elevated in the identified genotypes compared to the 1G/1G and 5A/5A genotypes, respectively. The transcriptional activity of MMPs-1,3 showed strong potential for distinguishing patients with epithelial ovarian carcinoma (EOC) from controls, boasting an area under the curve (AUC) of 0.956 and 0.816, respectively. Sensitivity and specificity were 94.0% and 90.0% for MMP-1 and 80.0% and 73.3% for MMP-3, respectively. Conclusions: The MMP-1 2G/2G and MMP-3 6A/6A genotypes are correlated with elevated MMP-1 and MMP-3 levels and immunohistochemical expression in carcinomatous ovarian tissues, particularly in advanced stages of OC. This indicates that genetic variations of MMPs-1,3 could be valuable diagnostic and prognostic markers for OC in Egyptian women. Our findings may carry clinical relevance for optimizing OC therapeutic effectiveness, contribute to the growing body of knowledge on the role of MMPs, and shed new light on the genetic background of OC. Future studies with larger sample sizes and comprehensive MMP genetic profiling are needed for results validation.